Rigel Pharmaceuticals Stock
Rigel Pharmaceuticals, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Raul R. Rodriguez
- Employees
- 173
- Market cap
- $859 M
- IPO
- 29/11/2000
Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States. The company offers TAVALISSE, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune…
Rigel Pharmaceuticals stock: price history
1D
-2.7%
1W
-6.3%
1M
+3.3%
6M
+41.8%
YTD
+7.3%
1Y
+63.5%
2Y
+194.1%
5Y
+36.0%
10Y
+38.5%
Next earnings date
Next earnings date
03/11/2026 (in 17 days)
Volatility around earnings
~32% stronger price swings than usual
Ask the agents about Rigel Pharmaceuticals
Analyst assessment of Rigel Pharmaceuticals
PRICE TARGET LOW
US$49.00
CONSENSUS
US$67.00
MEDIAN
US$67.00
PRICE TARGET HIGH
US$85.00
0
STRONG BUY
8
BUY
7
HOLD
0
SELL
0
STRONG SELL
15
TOTAL · Buy
As of: 17/08/2026
Rigel Pharmaceuticals stock metrics
P/E
2.6
P/B
2
EV/EBITDA
8.91
RETURN ON EQUITY
4.1%
NET MARGIN
22.0%
DEBT/EQUITY
0.09
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
96.7%
FLOAT SHARES
18,059,522
AVG. DAILY VOLUME (30D)
227,322
Insider transactions (SEC)
Furey Raymond J.
Schorno Dean L
Schorno Dean L
Schorno Dean L
Schorno Dean L
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: -2.7%
Forums (Reddit)
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Rigel Pharmaceuticals stock
What does Rigel Pharmaceuticals do?
Rigel Pharmaceuticals, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Raul R. Rodriguez, the company employs around 173 people.
The IPO was on 29/11/2000; the stock trades on NASDAQ under the ticker RIGL.
What do analysts say about Rigel Pharmaceuticals stock?
15 analysts rate the stock, the consensus is Buy (as of 17/08/2026).
The average price target is US$67.00, ranging from US$49.00 to US$85.00, with a median of US$67.00.
This is an external assessment, not a statement by Market Jury.
When does Rigel Pharmaceuticals report next?
The next earnings date is 03/11/2026.
Around past earnings, price swings were roughly 32% stronger than usual.
Does Rigel Pharmaceuticals pay a dividend?
No, Rigel Pharmaceuticals currently does not pay a dividend.
Which stocks are comparable to Rigel Pharmaceuticals?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Rigel Pharmaceuticals stock analyzed?
Clicking "Analyze stock" lets five strategies assess Rigel Pharmaceuticals against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.